UCLA researchers have found the human gut to be a major reservoir harboring the HIV virus holding almost twice as much as a persons blood. In addition, the virus stored in the gut does not decay or reduce over time, as is also the case with blood-related reservoirs. It is well-known that peripheral blood mononuclear cells (PBMCs) and lymph nodes are principal reservoirs harboring the human immunodeficiency virus (HIV). The role of gut-associated lymphoid tissue (GALT) in this setting, however, had not been properly evaluated until now. Researchers from the Center for Prevention Research and the UCLA AIDS Institute at the David Geffen School of Medicine at UCLA, in collaboration with the AIDS Research Alliance in West Hollywood, Calif., collaborated on this research.
The findings further confirm that HIV remains persistent and elusive, and that eradicating the virus using current anti-retroviral therapy alone is not enough. Despite using fully suppressive therapy, patients in the study still had evidence of persistent, steady levels of HIV in gut tissue as well as in the blood.
The authors of the study are W. John Boscardin, Julie Elliott, Philip Taing, Marie M.P. Fuerst, Ian McGowan and Peter A. Anton of UCLA; Michael A. Poles of New York University; and Stephen Brown of the AIDS Research Alliance. The research was published in the September issue of the Journal of Acquired Immune Deficiency Syndromes, and supported by grants from the National Institutes of Healths Centers for AIDS Research (CFAR): Cores of Mucosal Immunology, Virology and Biostatistics; AIDS Research Alliance; Macys Foundation; Pendleton Foundation, and Oppenheimer Brothers Foundation.
Source: UCLA
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.